Caribou Biosciences, Inc. (NASDAQ:CRBU) Receives $10.33 Consensus PT from Analysts

Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) have earned a consensus rating of “Buy” from the five ratings firms that are presently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average 1 year target price among analysts that have issued a report on the stock in the last year is $10.33.

CRBU has been the subject of a number of research reports. Citigroup decreased their price objective on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 26th. Bank of America decreased their price objective on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Caribou Biosciences in a research note on Friday, November 15th.

Caribou Biosciences Trading Up 0.9 %

CRBU stock opened at $1.17 on Wednesday. Caribou Biosciences has a twelve month low of $1.11 and a twelve month high of $8.22. The company has a market capitalization of $105.95 million, a P/E ratio of -0.71 and a beta of 2.31. The firm has a 50 day simple moving average of $1.49 and a 200-day simple moving average of $1.85.

Institutional Investors Weigh In On Caribou Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its stake in shares of Caribou Biosciences by 6.5% during the 3rd quarter. Geode Capital Management LLC now owns 2,030,443 shares of the company’s stock worth $3,980,000 after purchasing an additional 124,782 shares in the last quarter. Barclays PLC raised its stake in shares of Caribou Biosciences by 122.4% during the 3rd quarter. Barclays PLC now owns 129,839 shares of the company’s stock worth $255,000 after purchasing an additional 71,463 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Caribou Biosciences by 19.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 739,530 shares of the company’s stock worth $1,449,000 after purchasing an additional 118,325 shares in the last quarter. FMR LLC raised its stake in shares of Caribou Biosciences by 7.4% during the 3rd quarter. FMR LLC now owns 1,581,493 shares of the company’s stock worth $3,100,000 after purchasing an additional 109,606 shares in the last quarter. Finally, Green Alpha Advisors LLC raised its stake in shares of Caribou Biosciences by 75.4% during the 4th quarter. Green Alpha Advisors LLC now owns 181,054 shares of the company’s stock worth $288,000 after purchasing an additional 77,840 shares in the last quarter. 77.51% of the stock is owned by hedge funds and other institutional investors.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.